Project
An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD 20+ malignant disease
Automatically Closed · 2009 until 2013
Driessen Christoph, Hitz Felicitas, Hofmann Erika
Type
Range
Units
Status
Start Date
End Date
Financing
Study Design
Keywords
Additional Information
Brief description/objective
On open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO 5072759 given as monotherapy in patients with CD20+ malignant disease.
The site KSSG is participating in the phase II part of the study in which RO 5072759 will be randomized against the comparator drug rituximab (MabThera).